Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Isis Pharmaceuticals, Inc.

Walter and Eliza Hall Institute of Medical Research

Msd R&d (china) Co., Ltd.

Other

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp & Dohme De Espana Sa

Merch Sharpe & Dohme LLC

Hewlett-packard Development Company, L.P.

Hewlett-packard Company

Hewlett Packard Enterprise Development LP

Ionis Pharmaceuticals, Inc.

Msd R&d Co., Ltd.

David Brian Olsen

Joseph P Vacca

Qun Dang

Lihu Yang

John A McCauley

Vinay M Girijavallabhan

Phillip Dan Cook

Stephane L Bogen

F George Njoroge

Nigel J Liverton

Balkrishen Bhat

Frank W Bennett

Michael T Rudd

Ian W Davies

Jing Su

Andrew William Stamford

Thazha P Prakash

Malcolm MacCoss

Ashok Arasappan

Sheo B Singh

Philippe G Nantermet

Dmitri A Pissarnitski

Ralph L Stathem

Bin Hu

Judson Malcolm Leiser

Ying Huang

Robert R Wilkening

Malcolm Maccoss

Miquel Boleda Busquets

Michael E Peterschmidt

Zhuyan Guo

Dongfang Meng

Joseph A Kozlowski

Wesley R Schalk

Jared N Cumming

Anthony Donald Studer

Deborah L Zink

Curt G Gonzales

Paul Mark Haines

Tony S Cruz-Uribe

Patrick V Boyd

Mark A Devries

Patrick J Therien

Gabor Butora

David C Harvey

Sanjib Bera

Ronald J Ender

Jianmin Fu

Haoyun An

Steven T Castle

Takao Suzuki

Anne Bettina Eldrup

Lawrence C Kuo

M Katharine Holloway

Steven W Ludmerer

Marija Prhavc

Manuel De Lera Ruiz

Bernd Karlsboeck

Latha G Nair

Frank Narjes

Charles John Guinosso

Kevin D Almen

David D Welter

James L Cole

Angela Dawn Kerekes

Vishal Verma

Wolfgang A Pieken

Fritz Eckstein

Steven S Carroll

Fritz Benseler

David M Williams

Brendan M Crowley

Mihir Mandal

Katherine Young

Lanying You

Michael J Kelly, Iii

Charles J McIntyre

James M Apgar

Quanlai Song

Dann Parker

Ping Chen

Tanweer A Khan

Steven Harper

Brad E Sleebs

Quang T Truong

Michael A Goetz

Cristina Gardelli

Lynn A Collie

Roger J Kolodziej

Paul Allan Osborne

Francisca Vicente

Jon D Polishook

Zhibo Zhang

Milo A Undlin

Rory A Heim

Robert L LaFemina

Olga Genilloud

Barbara Pacini

Monica Donghi

Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and Rare as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Compounds and methods of use thereof as antibacterial agents

The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections byby administering a therapeutically effective amount of Formula (I) and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compound and methods of use thereof as an antibacterial agent

The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compounds and methods of use thereof as antibacterial agents

Methods of treating malaria comprising administration of compounds of Formula (I') or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating ainfection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Antimalarial agents

The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating ainfection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R, R, R, R, R, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating ainfection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

N3-substituted iminopyrimidinones as antimalarial agents

The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and Rare as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections byby administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.

Nargenicin compounds and uses thereof as antibacterial agents

The present invention is directed to 4'-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

4'-substituted nucleoside reverse transcriptase inhibitors

The present invention relates to Cyclic Phosphonate Substituted Nucleoside Derivatives of Formula (I): (structure) and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein, as well as to compositions and methods of using the Cyclic Phosphonate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. 

Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

The present invention relates to 5'-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, Rand Rare as defined herein and B is a 7-deaza-9-purinyl moiety. The present invention also relates to compositions comprising at least one 5&#x2032;-Substituted Nucleoside Derivative, and methods of using the 5&#x2032;-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. 

5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

The present invention relates to 2'-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one 2&#x2032;-Azido Substituted Nucleoside Derivative, and methods of using the 2&#x2032;-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. 

2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

The present invention relates to 2'-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one 2&#x2032;-Cyano Substituted Nucleoside Derivative, and methods of using the 2&#x2032;-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. 

2'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases

The present invention relates to novel compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof that are useful in the treatment and/or prevention of human and animal bacterial infections and associated diseases and conditions; compositions containing such compounds; derivation of such compounds by fermentation and isolation, partial synthesis and total synthesis; methods of inhibiting bacterial growth; methods of treating, preventing or controlling bacterial infection; biologically pure cultures of bacterial strains from which such compounds may be produced; and processes for preparing compositions containing such compounds. 

Extracts from kibdelos porangium as antibacterial agents

Growing community of inventors

Lansdale, PA, United States of America

David Brian Olsen